公开(公告)号：WO2013147568A1

公开(公告)日：2013-10-03

申请号：PCT/KR2013/002699

申请日：2013-04-01

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： KIM, Dong Jin ,  YOO, Kyung Ho ,  KIM, Young Soo ,  PARK, Woong Seo ,  KANG, Yong Koo ,  KIM, Hye Yun ,  KIM, Yun Kyung ,  PARK, Ki Duk ,  KIM, Maeng Sup ,  SUH, Kwee Hyun ,  AHN, Young Gil

IPC: C07D413/12 ,  C07D307/86 ,  A61K31/421 ,  A61P25/00

CPC classification number: C07D413/12 ,  C07D307/81 ,  C07D405/12

Abstract: The present invention provides an aminostyrylbenzofuran compound of Formula (I), and a pharmaceutical composition comprising same. The pharmaceutical composition of the present invention comprising the compound of Formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate, and a solvate thereof as an active ingredient can be useful for the prevention and treatment of degenerative brain diseases caused by accumulation of beta-amyloid.

Abstract translation: 本发明提供式（I）的氨基苯乙烯基苯并呋喃化合物和包含其的药物组合物。 包含式（I）化合物，其药学上可接受的盐，异构体，水合物和溶剂合物作为活性成分的本发明的药物组合物可用于预防和治疗由积累引起的退行性脑病 的β-淀粉样蛋白。

公开(公告)号：WO2010005148A2

公开(公告)日：2010-01-14

申请号：PCT/KR2008/005784

申请日：2008-10-01

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  CHO, Yong Seo ,  PAE, Ae Nim ,  CHOO, Hyunah ,  LEE, Jae Kyun ,  OH, You Na ,  SHIN, Hee Sup ,  KIM, Dong Jin ,  HAHN, Hoh Gyu ,  CHOI, Kyung Il ,  NAM, Ghilsoo ,  SHIN, Kye Jung ,  KANG, Soon Bang ,  ROH, Eun Joo ,  SHIN, Dong Yun ,  SEO, Seon Hee ,  RHIM, Hyewhon ,  KEUM, Gyo Chang ,  KIM, Key-Sun ,  CHEONG, Chan Seong ,  KIM, Eunice Eun-Kyeong ,  LEE, Cheolju ,  KIM, Youngsoo ,  CHOI, Kee Hyun ,  NAM, Kee Dal ,  PARK, Woong Seo ,  KANG, Yong Koo ,  CHUNG, Hye Jin

Inventor： CHO, Yong Seo ,  PAE, Ae Nim ,  CHOO, Hyunah ,  LEE, Jae Kyun ,  OH, You Na ,  SHIN, Hee Sup ,  KIM, Dong Jin ,  HAHN, Hoh Gyu ,  CHOI, Kyung Il ,  NAM, Ghilsoo ,  SHIN, Kye Jung ,  KANG, Soon Bang ,  ROH, Eun Joo ,  SHIN, Dong Yun ,  SEO, Seon Hee ,  RHIM, Hyewhon ,  KEUM, Gyo Chang ,  KIM, Key-Sun ,  CHEONG, Chan Seong ,  KIM, Eunice Eun-Kyeong ,  LEE, Cheolju ,  KIM, Youngsoo ,  CHOI, Kee Hyun ,  NAM, Kee Dal ,  PARK, Woong Seo ,  KANG, Yong Koo ,  CHUNG, Hye Jin

IPC: C07D403/12

CPC classification number: C07D401/12 ,  A61K31/454

Abstract: Disclosed are isoindolinone derivatives having inhibitory activity against T-type calcium channels, pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition comprising the same as an active ingredient.

Abstract translation: 公开了对T型钙通道具有抑制活性的异吲哚啉酮衍生物，其药学上可接受的盐，其制备方法和包含其的作为活性成分的药物组合物。

公开(公告)号：WO2005121144A1

公开(公告)日：2005-12-22

申请号：PCT/KR2005/001798

申请日：2005-06-14

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  YOO, Kyung Ho ,  KIM, Dong Jin ,  KANG, Yong Koo ,  LEE, Kyung Seok ,  LEE, Gwan Sun ,  KIM, Maeng Sup ,  KANG, Jae Hoon

Inventor： YOO, Kyung Ho ,  KIM, Dong Jin ,  KANG, Yong Koo ,  LEE, Kyung Seok ,  LEE, Gwan Sun ,  KIM, Maeng Sup ,  KANG, Jae Hoon

IPC: C07D477/20

CPC classification number: C07D477/20

Abstract: The present invention relates to a novel 1β-methylcarbapenem derivative, a process for the preparation thereof and a pharmaceutical composition comprising the 1β-methylcarbapenem derivative or a pharmaceutically acceptable salt thereof as an active antibacterial ingredient.

Abstract translation: 本发明涉及一种新型的β-甲基碳青霉烯类衍生物，其制备方法和药物组合物，其包含作为活性抗菌成分的β-甲基碳青霉烯衍生物或其药学上可接受的盐。

公开(公告)号：EP3202759A1

公开(公告)日：2017-08-09

申请号：EP15847985.7

申请日：2015-09-24

Applicant: Korea Institute of Science and Technology

Inventor： PARK, Ki Duk ,  LEE, Changjoon Justin ,  KIM, Dong Jin ,  PAE, Ae Nim ,  CHOO, Hyun Ah ,  MIN, Sun Joon ,  KANG, Yong Koo ,  KIM, Yun Kyung ,  SONG, Hyo Jung ,  CHOI, Ji Won ,  NAM, Min Ho ,  HEO, Jun Young ,  YEON, Seul Ki ,  JANG, Bo Ko ,  JU, Eun Ji ,  JO, Seon Mi ,  PARK, Jong-Hyun

IPC: C07C237/20 ,  C07C237/04 ,  C07C231/12 ,  C07C309/04 ,  A61K31/16 ,  A61K31/167

Abstract: The present disclosure relates to an α-aminoamide derivative compound and a pharmaceutical composition containing the same. According to various embodiments of the present disclosure, provided is a therapeutic agent which can overcome the disadvantages of existing drugs used as a MAO-B inhibitor and, specifically, reversibly inhibits MAO-B through a non-covalent bond so as to alleviate or eliminate the side effects of the existing drugs which exhibit a therapeutic effect by irreversibly acting via a covalent bond with MAO-B. Particularly, a new compound having superior stability and efficacy compared to the existing reversible MAO-B inhibitors may be provided.

Abstract translation: 本公开涉及α-氨基酰胺衍生物化合物和含有其的药物组合物。 根据本公开的各种实施方式，提供了一种治疗剂，其可以克服现有药物用作MAO-B抑制剂的缺点，并且具体地通过非共价键可逆地抑制MAO-B，从而缓解或消除 现有药物通过与MAO-B通过共价键发挥不可逆作用而表现出治疗效果的副作用。 特别地，可以提供与现有可逆MAO-B抑制剂相比具有优良稳定性和功效的新化合物。